Acquiring Company
BioMarin Pharmaceutical
Acquired Company
Amicus Therapeutics
San RafaelPrincetonBiotechnologyHealth CareMedicalGeneticsTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
BioMarin Pharmaceutical Inc. has announced its agreement to acquire Amicus Therapeutics for approximately $4.8 billion, or $14.50 per share in cash. This acquisition aims to enhance BioMarin's product portfolio by adding key treatments for rare diseases. The transaction is expected to close in the second quarter of 2026, pending regulatory approvals and stockholder votes.
Quick answer
BioMarin Pharmaceutical is acquiring Amicus Therapeutics for $4.8 billion, announced December 19, 2025. BioMarin Pharmaceutical is based in San Rafael, California, United States.
- How much did BioMarin Pharmaceutical pay for Amicus Therapeutics?
- The reported deal value is $4.8 billion.
- What does BioMarin Pharmaceutical do?
- BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery.
- Where are BioMarin Pharmaceutical and Amicus Therapeutics based?
- BioMarin Pharmaceutical is based in San Rafael, California, United States. Amicus Therapeutics is based in Princeton, New Jersey, United States.
- Who are the decision-makers at BioMarin Pharmaceutical?
- Fundz holds 1 contact at BioMarin Pharmaceutical. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Genetics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Galecto, Inc. Acquires Damora Therapeutics, Inc. (November 10, 2025)
- AbbVie to acquire Revolution Medicines soon (January 9, 2026)
- Pfizer completes $43 billion acquisition of Seagen, $43B (January 4, 2026)
- BioNTech completes acquisition of CureVac (December 20, 2025)
- Day One to acquire Mersana for $130 million, $130M (November 30, 2025)
- ClearPoint Neuro acquires IRRAS for $5 million, $5M (November 20, 2025)
Who to call at BioMarin Pharmaceutical, and when
When BioMarin Pharmaceutical changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioMarin Pharmaceutical raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioMarin Pharmaceutical, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioMarin Pharmaceutical. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioMarin Pharmaceutical makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Amicus Therapeutics?
Amicus Therapeutics was acquired by BioMarin Pharmaceutical, based in San Rafael. The deal was reported on December 19, 2025. BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. BioMarin Pharmaceutical is publicly traded (BMRN) and operates in Biotechnology.
When did BioMarin Pharmaceutical acquire Amicus Therapeutics?
BioMarin Pharmaceutical's acquisition of Amicus Therapeutics was reported on December 19, 2025. BioMarin Pharmaceutical Inc. has announced its agreement to acquire Amicus Therapeutics for approximately $4.8 billion, or $14.50 per share in cash. This acquisition aims to enhance BioMarin's product portfolio by adding key treatments for rare diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Amicus Therapeutics do?
We are leveraging our innovative technology platforms to develop treatments for human genetic diseases. Join a team committed to changing the lives of patients with rare metabolic diseases. Now hiring in multiple locations. It is privately held, operating in Biotechnology, and is based in Princeton.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.